Universal CAR-T therapy takes on tough cancers
NCT ID NCT06653023
First seen Jan 26, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This early-phase study tests a new type of immune cell therapy called universal CAR-T cells in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The therapy targets a protein called GPC3 found on these cancer cells. The main goals are to find the safest dose and to see if the treatment can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Conditions
Explore the condition pages connected to this study.